- Home
- PCRX vs ADPT Comparison
PCRX vs ADPT Comparison
Compare PCRX & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCRX
- ADPT
- Stock Information
- Founded
- PCRX 2006
- ADPT 2009
- Country
- PCRX United States
- ADPT United States
- Employees
- PCRX N/A
- ADPT N/A
- Industry
- PCRX Biotechnology: Pharmaceutical Preparations
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PCRX Health Care
- ADPT Health Care
- Exchange
- PCRX Nasdaq
- ADPT Nasdaq
- Market Cap
- PCRX 1.2B
- ADPT 1.2B
- IPO Year
- PCRX 2011
- ADPT 2019
- Fundamental
- Price
- PCRX $25.16
- ADPT $8.27
- Analyst Decision
- PCRX Buy
- ADPT Buy
- Analyst Count
- PCRX 9
- ADPT 5
- Target Price
- PCRX $26.22
- ADPT $9.10
- AVG Volume (30 Days)
- PCRX 805.4K
- ADPT 1.5M
- Earning Date
- PCRX 02-27-2025
- ADPT 02-11-2025
- Dividend Yield
- PCRX N/A
- ADPT N/A
- EPS Growth
- PCRX N/A
- ADPT N/A
- EPS
- PCRX N/A
- ADPT N/A
- Revenue
- PCRX $694,957,000.00
- ADPT $178,957,000.00
- Revenue This Year
- PCRX $5.55
- ADPT $20.67
- Revenue Next Year
- PCRX $5.64
- ADPT $21.79
- P/E Ratio
- PCRX N/A
- ADPT N/A
- Revenue Growth
- PCRX 4.40
- ADPT 5.10
- 52 Week Low
- PCRX $11.16
- ADPT $2.28
- 52 Week High
- PCRX $31.67
- ADPT $8.95
- Technical
- Relative Strength Index (RSI)
- PCRX 52.48
- ADPT 58.94
- Support Level
- PCRX $25.41
- ADPT $8.09
- Resistance Level
- PCRX $26.89
- ADPT $8.69
- Average True Range (ATR)
- PCRX 1.18
- ADPT 0.64
- MACD
- PCRX -0.36
- ADPT -0.00
- Stochastic Oscillator
- PCRX 4.35
- ADPT 65.66
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).